United States of America based
Palleon Pharmaceuticals develops drugs that target sugar-sensing molecules on the surfaces of cells. It has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glycoimmune Checkpoint Inhibitors to treat cancer patients.
TechnologiesPharmaceutical and Drug Discovery
No pipelines published yet
No services posted yet